Securities Purchase Agreement On May 23, 2025, the Issuer entered into a Securities Purchase Agreement (the "SPA") with M3-Brigade Sponsor V LLC, a Delaware limited liability company (the "Original Sponsor"), and the New Sponsor, pursuant to which the Original Sponsor agreed to sell, and the New Sponsor agreed to purchase, 7,187,500 Class B ordinary shares, par value $0.0001 per share (the "Class B Ordinary Shares"), and 5,043,750 private placement warrants of the Issuer owned by the Original Sponsor (collectively, the "Transferred Sponsor SPAC Securities") for an aggregate purchase price of $6,467,500 (the "Closing Cash Purchase Price"). The Class B Ordinary Shares can be converted into Class A Ordinary Shares on a one-for one basis (the Class B Ordinary Shares, and together with the Class A Ordinary Shares, the "Common Shares"). The transactions contemplated by the SPA were consummated on May 27, 2025 (the "Closing"). At the Closing, the Original Sponsor delivered to the New Sponsor an assignment of the Transferred Sponsor SPAC Securities against payment of the Closing Cash Purchase Price. Also on May 27, 2025, the New Sponsor entered into an agreement to purchase 3,293,750 additional private placement warrants of the Issuer from Cantor Fitzgerald & Co. (the "Cantor Warrants"). Under the SPA, the Original Sponsor was required to deliver resignations, effective as of the Closing, of such directors and officers of the Issuer as may be requested by the New Sponsor in writing on or prior to the day immediately preceding the Closing. In addition, the New Sponsor was permitted to designate director nominees for the Board of Directors of the Issuer (the "Board") and designate the Chief Executive Office, Chief Financial Officer, and Executive Vice President of the Issuer. Under the SPA, the Issuer was required to appoint such directors and officers, effective as of the Closing. The Reporting Persons acquired the position in the Common Shares of the Issuer in the belief that the Common Shares represented an attractive investment opportunity. The Reporting Persons intend to engage in discussions with members of the Board regarding a potential business combination in the crypto asset space potentially with an affiliate of the Reporting Persons. In addition, the Reporting Persons intend to review their investment in the Issuer on a continuing basis and may from time to time and at any time in the future depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Board, price levels of the Common Shares, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, take such actions with respect to their investments in the Issuer as they deem appropriate. These actions may include, without limitation: (i) acquiring additional Common Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are convertible into Common Shares, or are based upon or relate to the value of the Common Shares or the Issuer (collectively, "Securities") in the open market or otherwise; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D. As President of the Issuer, Mr. Chu will have discussions with the Chief Executive Officer and the Board of the Issuer regarding the above. Letter Agreement On July 31, 2024, the Issuer entered into a letter agreement with the Original Sponsor and the Issuer's officers and directors (the "Letter Agreement"). Under the Letter Agreement, the Original Sponsor and the Issuer's officers and directors agreed (1) to vote their founder shares and any Class A Ordinary Shares in favor of the Issuer's initial business combination; (2) to waive their redemption rights with respect to their founder shares and Class A Ordinary Shares in connection with the completion of the Issuer's initial business combination or an earlier redemption in connection with the commencement of the procedures to consummate the initial business combination if the Issuer determines that it is desirable to facilitate the completion of the initial business combination; and (3) to waive their rights to liquidating distributions from the trust account with respect to their founder shares if the Issuer fails to complete an initial business combination within the prescribed time frame. Furthermore, the Original Sponsor and the Issuer's officers and directors agreed not to transfer, assign or sell any of their founder shares and any Class A Ordinary Shares issuable upon conversion thereof until the earlier to occur of: (i) one year after the completion of an initial business combination or (ii) subsequent to the initial business combination, (A) if the closing price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial business combination or (y) the date on which the Issuer completes a liquidation, merger, share exchange or other similar transaction that results in all of the Issuer's shareholders having the right to exchange their Class A Ordinary Shares for cash, securities, or other property. Assignment and Assumption of Letter Agreement Pursuant to the SPA, the Issuer entered into an Assignment and Assumption Agreement with the New Sponsor, the Original Sponsor and the Issuer's directors and executive officers, pursuant to which the Original Sponsor assigned to the New Sponsor, and the New Sponsor assumed, all of the Original Sponsor's rights, title and interests under the Letter Agreement, and the New Sponsor agreed to be bound by all terms, conditions, and covenants and be entitled to all the terms and provisions therein. Letter Agreement Waiver Pursuant to the SPA, the Issuer entered into a limited waiver with the Issuer's directors and executive officers, the Original Sponsor and the New Sponsor (the "Limited Waiver"). Pursuant to the Limited Waiver, the parties to the Letter Agreement agreed to waive the transfer restrictions contained in Section 7 thereof to the extent necessary or desirable to facilitate the sale of the Transferred Sponsor SPAC Securities contemplated by the SPA and to facilitate the transfer of the Cantor Warrants. Registration Rights Agreement On July 31, 2024, the Issuer entered into a Registration Rights Agreement with the Original Sponsor and Cantor Fitzgerald & Co. (the "Registration Rights Agreement"). Under the Registration Rights Agreement, the Original Sponsor and their permitted transferees can demand that the Issuer register the founder shares and the Class A Ordinary Shares into which founder shares are convertible, holders of the Issuer's private placement warrants and their permitted transferees can demand that the Issuer register the private placement warrants and the Class A Ordinary Shares issuable upon exercise of the private placement warrants or holders of securities that may be issued upon conversion of working capital loans and their permitted transferees may demand that the Issuer register such shares, warrants or the Class A Ordinary Shares issuable upon exercise of such warrants and any other securities of the Issuer acquired by them prior to the consummation of the Issuer's initial business combination. Assignment and Assumption of Registration Rights Agreement Pursuant to the SPA, the Issuer entered into an Assignment and Assumption Agreement with the New Sponsor, the Original Sponsor and Cantor Fitzgerald & Co., pursuant to which the Original Sponsor assigned to the New Sponsor, and the New Sponsor assumed, all of the Original Sponsor's rights, title and interest under the Registration Rights Agreement, and the New Sponsor agreed to be bound by the terms and provisions therein. Director Appointments Effective May 27, 2025, in connection with the SPA, (i) Thomas L. Fairfield was appointed to the Board as a Class II director; and (ii) Ted Murphy was appointed to the Board as a Class I director. In addition, effective May 27, 2025, each of Messrs Fairfield and Murphy and Benjamin Fader-Rattner was appointed to the Audit Committee, with Mr. Murphy serving as its chair, and each of Messrs Fairfield, Murphy and Fader-Rattner was appointed to the Compensation Committee and the Corporate Governance and Nominating Committee, with Mr. Fairfield serving as chair of both committees. Effective May 27, 2025, Mohsin Y. Meghji will no longer serve as Executive Chairman but will remain on the Board as Chairman. Officer Resignation and Appointments Effective May 27, 2025, in connection with the SPA, (i) Matthew Perkal resigned as the Chief Executive Officer and was appointed as Chief Operating Officer; and (ii) the Board appointed Mr. Chu as President and Reeve Collins as Chief Executive Officer of the Issuer.